New Key Statistics Module, Z-Score and F-Score
NAS:ENTA Key Ratios
| Market Cap $ M | 107.88 |
| Enterprise Value $ M | -84.84 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 0.84 |
| Price/Sales | 1.59 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 67.00 |
| EPS (TTM) $ | -5.48 |
| Beneish M-Score | -3.12 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 0.79 |
| EV-to-EBITDA | 0.81 |
| PEG | -- |
| Shares Outstanding M | 21.19 |
| Net Margin (%) | -171.58 |
| Operating Margin % | -179.92 |
| Pre-tax Margin (%) | -174.15 |
| Quick Ratio | 5.21 |
| Current Ratio | 5.21 |
| ROA % (ttm) | -27.90 |
| ROE % (ttm) | -68.06 |
| ROIC % (ttm) | -115.49 |
| Dividend Yield % | -- |
| Altman Z-Score | -0.92 |
ENTA Number of Guru Trades
ENTA Volume of Guru Trades
Gurus Latest Trades with NAS:ENTA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ENTA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Enanta Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:ENTA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers